Management Team

Our management team is highly experienced in a variety of relevant sectors, from molecular biology and genetics to pharmaceutical development, BD deals and corporate finance. This combination of skill sets enables the team to effectively execute our business plan.

DHS photo.jpeg

Dr. David Horn Solomon

Chief Executive Officer

RQ photo2.jpg

Dr. Rob Quinn

Interim Chief Financial Officer

Dr. David Horn Solomon

Chief Executive Officer

David is an experienced public company biotech CEO, board member and biotech investor. He was the CEO of Zealand Pharma A/S (NASDAQ:ZEAL) from 2008 to 2015. Under David’s leadership the company went public on NASDAQ OMX and its lead product, Adlixin®, a GLP-1 receptor agonist for the treatment of type II diabetes, was approved in the US and globally and is now marketed by Sanofi as a monotherapy and in combination with Lantus as Soliqua®. David was also the CEO of Bionor Pharma ASA (OSL:BIONOR) and Akari Therapeutics, Plc (NASDAQ:AKTX), and was the Managing Partner of Sund Capital, ApS, a Nordic healthcare investment fund.

He has earlier served as a faculty member at Columbia University’s College of Physicians and Surgeons in New York City. From 2003 to 2006, David headed healthcare investment at Carrot Capital Healthcare Ventures in New York. David is currently a member of the Board of Directors of TxCell SA (NYSE EURONEXT:TXCL), and was earlier a member of the Boards at Onxeo SA (NYSE EURONEXT:ONXEO) and Promosome, LLC. Dr Solomon studied at Weil Cornell Medicine of Cornell University and its Graduate School of Medical Science where he received his Ph.D.

DHS photo.jpeg

Appointed

July 2018

Areas of expertise

Biotech corporate finance, pharmaceutical development, business development agreements, biotech governance

Current external roles

Director of TxCell SA

Dr. Rob Quinn

Interim Chief Financial Officer

Rob was appointed as Interim Chief Financial Officer and Company Secretary of Silence in January 2019. Rob holds a PhD in Biochemistry from the University of Manchester and is a qualified chartered accountant.

Following his PhD Rob trained as an accountant at Deloitte before joining GlaxoSmithKline (2013-2017), with time spent working in internal audit, M&A and commercial finance. Rob’s last role at GSK was as Area Finance Director for the Africa & Developing Countries business unit, covering sales of pharmaceuticals and vaccines to over 45 countries. Rob joined Silence in April 2017 as Head of Financial Planning and Analysis before broadening his responsibilities to Legal, IT and Manufacturing.

RQ photo2.jpg

Appointed

January 2019